Guidance on health economic modelling of personalised medicine in Europe and review of evidence of the value of personalised medicine
Lead partner: iMTA
WP1 will:
- Provide a systematic review of existing model-based economic evaluations of personalised medicine, considering the specific modelling characteristics that are required to fully represent the (value of) treatment pathways in personalised medicine
- Identify best practices of health economic modelling of personalised medicine
- Develop guidance on health economic modelling of personalised medicine to inform pricing and reimbursement decisions and clinical guidelines
- Conclude on current estimates of the value of personalised medicine